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Proton MR spectroscopy of the mammary gland area is used to be considered in the realm of basic research, but as a result of the
advances in MR techniques, it is now being performed in ordinary clinical practice. It is particularly noteworthy that useful clinical
data are now being accumulated with 1.5TMR units, which are the standard units. We think that, at this point, it is very important
to systematically review the techniques, clinical applications, and future prospects of proton MR spectroscopy. We have performed
proton MR spectroscopy with a 1.5TMR unit in over 3000 cases at our hospital. In this paper, we will comment on the current
status of proton MR spectroscopy of the breast, primarily in regard to diﬀerentiation between benign and malignant lesions and
prediction of the eﬃcacy of chemotherapy while describing the data obtained at our hospital.
1.Introduction
MRI of the breast has been applied clinically for more than
20 years, and in Western countries methods of using, it
has been established in the form of guidelines [1, 2]. The
core applications of MRI of the breast lie in detecting,
diagnosing, and evaluating the eﬃcacy of treatment of breast
cancer [1, 2]. Today, however, besides the information on
tumor morphology and blood ﬂow obtained by contrast-
enhanced MRI, it has become possible to obtain a variety of
function images and molecular information, and PET and
MR spectroscopies are representative studies that are capable
of actually being used clinically.
Choline is considered an important metabolite in proton
MR spectroscopy in the mammary gland area. Cholines are
substances that have attracted interest in regard to every
organ and disease, and because they are precursors of the
phospholipids that compose cell membranes, increases in
choline signals are thought to reﬂect increased membrane
synthesis. In the mammary gland area, choline shows a
promise of enabling diﬀerentiation between benign and
malignant tumors and of serving as an indicator of tumor
activity and viability. Clinically, the attention has been
f o c u s e do nd i ﬀerentiation between benign and malignant
tumors and prediction of the eﬃcacy of chemotherapy.
2. Metabolites Observed by Proton MR
Spectroscopy of the Breast
The markers that are useful in breast diseases are centered
at 3.2ppm and are generally referred to as the choline peak.
However, myo-inositol, taurine, and so forth are included in
the choline peak in addition to such compounds as choline
(Cho), phosphocholine (PC), and glycerophosphocholine
(GPC), which are parts of the membrane lipid metabolic
pathways, and because of the closeness of the ranges of their
chemical shifts, they are observed as a single peak when
measurements are made in vivo.
At the cellular level, GPC is higher than PC in normal
breast tissue, and since a marked increase in PC and
decrease in GPC have been demonstrated as a result of
carcinogenesis [3], the main component in breast cancer is
PC [3]. Moreover, it has been reported that if we examine
minute chemical shifts even with a 1.5TMR unit, it is
possible to separate and observe a 3.22-3.23ppm (PC) peak2 Journal of Oncology
and a 3.27-3.28ppm peak (GPC/taurine/myo-inositol), and
that they are useful in diﬀerentiating between benign and
malignant tumors [4].
Anotherpeakobservedbesidescholineisthelactosepeak
(3.8ppm). The lactose peak is characteristic of the lactation
period, and choline has also been found to be detected at
3.2ppm during that period [5]. The choline observed in the
lactating breast matches the choline (3.27ppm) observed in
benign diseases [4, 6].
3. Basic Summation:ImagingTechniques
Knowledge of imaging techniques is essential for proton MR
spectroscopy of the breast. We will comment on each of the
basic items in relation to imaging.
3.1.VoxelSize. Incontrasttothecentralnervoussystemarea,
because of the presence of normal tissue, fat, and so forth, in
the mammary glands, the magnetic ﬁelds in the voxels tend
to be nonhomogeneous. Thus, when analyzing the spectra of
tumors, it is important to set the voxels so that tissue outside
the tumor is excluded. However, because there is a tradeoﬀ
between voxel size and acquisition time, a certain voxel size
is unavoidable in order to obtain a high signal-to-noise ratio
(SNR).
Assuming the addition of MR spectroscopy before or
after approximately 20 to 30 minutes contrast-enhanced
MRI, we think being able to perform MR spectroscopy in
approximately 10 minutes would be ideal, and a minimum
voxel size of about 15mm × 15 mm × 15mm would
thereforeappeartobeappropriateforlesionswithadiameter
of 1cm or greater.
3.2. Shimming. In contrast to the central nervous system,
manual shimming as well as autoshimming is essential to
make the magnetic ﬁelds of the voxels homogeneous. With
manual shimming, we use full width at half-maximum
(FWHM) or T2∗ for reference, and 20–30Hz is the approxi-
mate target for FWHM.
3.3. Sequence. When the tumor is large, chemical shift
imaging (CSI) is sometimes even used as a means of assess-
ing the internal nonhomogeneity of the tumor (Figure 1).
However, because multivoxelization is performed by using
the point spread function by phase encoding, the same
as for MRI, contamination from adjacent voxels occurs.
Because of this defect, single-voxel spectroscopy is now
the standard method. A spin-echo type, point-resolved
spectroscopy sequence (PRESS) [7] is generally used in order
to obtain single-voxel spectroscopy data.
When selecting echo time (TE) of proton MR spec-
troscopy, the decision as to whether to use a short TE or
long TE involves making a tradeoﬀ between signal intensity
and signal contrast. A high SNR is obtained with short TE
whereas long TE is superior in terms of ability to separate
the contrast signal from the fat signal. With long TE (135–
270ms), the signal intensity decreases, but the fact that the
fat signal also decreases means an improvement in ability to
detect the choline signal [8].
3.4. Fat Suppression. Application of MR spectroscopy to
the whole body has recently increased greatly, and many
methods of fat suppression have been developed. Band-
selective inversion with gradient dephasing (BASING) [9]
is one of the latest fat suppression techniques and makes
it possible to suppress any chemical shift spectrum signal
desired by incorporating an additional pulse into the PRESS
sequence. The pulses used for suppression, such as chemical-
shift selective (CHESS) excitation pulses [10], are positioned
in the form of prepulses immediately before the excitation
pulses whereas with BASING the pulses for suppression are
positioned within the body of the sequence itself. BASING
enables suppression of the peak of any chemical shift desired,
and it has been applied to peak editing, and so forth. This
method is characterized by being little aﬀected by T1 or B1.
3.5. Water Suppression. It is preferable for the water peak
to persist to some extent in order to be able to use it as
a standard to compute the chemical shift of a metabolite.
While it is possible to perform water and fat suppression
simultaneously by BASING, we use CHESS for water sup-
pression at our hospital because of its strong suppressive
eﬀect. It is possible to set the intensity of the residual water
peak by setting the waiting time after applying the CHESS
pulse. We actually set the waiting time after applying the
CHESS pulse at 200ms.
3.6. Quantiﬁcation. Two methods are available for quantiﬁ-
cation when performed by comparison with known concen-
trations: the internal reference method [11] and the external
reference method [12]. In the internal reference method, the
water signals in measurement voxels are used to quantify
the target metabolites, whereas in the external reference
method, a phantom is set up close to the measurement
site, and the concentration in the volume in the phantom
is used as the standard. Both methods have advantages
and disadvantages. We use the external reference method to
perform quantiﬁcation at our hospital.
With the internal reference method, the water content
of the voxels changes during chemotherapy [13], and that
is a potential pitfall with using it. That is why the external
reference method was chosen at our hospital. The greatest
disadvantage of the external reference method is the need
to perform an additional independent measurement as an
external reference, and it also requires correction for the
partial volume eﬀect and separate calibration experiments.
Furthermore, since the T1 and T2 values of choline used
were the values cited, there is the possibility of errors being
introduced between these values and the actual values in the
patients.Inaddition,becauseofpatientmovements,accurate
correction is diﬃcult even with frequency correction. Thus,
the quantiﬁcation method itself is beset with several prob-
lems.
As stated above, quantiﬁcation is still challenging. How-
ever, quantiﬁcation is essential in order to compare changesJournal of Oncology 3
in the amount of choline for the patients treated with
neoadjuvant chemotherapy. We believe that quantiﬁcation
is very useful and requires dedicated multidisciplinary team
including radiologists, medical physicists, physicists, and
chemists.
3.7. Imaging Method at Our Hospital. At our hospital, we
perform proton MR spectroscopy with a 1.5T unit (MAG-
NETOM Avanto; Siemens AG Healthcare Sector, Erlangen,
Germany) and circularly polarized (CP) and four-channel
phased-array breast coil (breast matrix coil; Siemens AG
Healthcare Sector, Erlangen, Germany) [6]. The parameters
used for MR spectroscopy are TR/TE = 1620/270; voxel size
= 15 × 15 × 15mm3; acquisitions = 256; spectral width =
1,000Hz; data points = 1,024; and the time of acquisition is 7
minutes. Postcontrast coronal and sagittal T1-weighted MR
images are used as scout images for voxel placement.
We have tried performing the following procedure for
quantiﬁcation by the external reference method.
A cylindrical bottle phantom (syngo GRACE external
phantom; Siemens AG Healthcare Sector, Erlangen, Ger-
many) 4.0cm high and 2.5cm in diameter was inserted
behind the breast coil and ﬁxed in position. The phantom
was ﬁlled with 1.25g of NiSO46H2O per 1000g of H2O.
Proton MR spectroscopy of the phantom was performed
immediately after the MR spectroscopy examination of
the breast lesion. The scan was performed without water
suppression. The voxel size was 7 × 7 × 15mm3, and the
acquisition time was 4 seconds.
The following formula was used to calculate the scaling
factor:
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(1)
wherenCho andnH2O arethenumbersof 1Hnucleiofcholine
molecules and water molecules, respectively. The scaling
factor can be converted to molar concentration by correcting
for the number of 1H nuclei per molecule and the molecular
weight of the solvent (MWH2O). The fT1 and fT2 relaxation
factors were corrected by using the equation for relaxation
times.
The relaxation times (T1 and T2) of the phantom
water were measured. T1 was calculated from the images
obtained with two diﬀerent TRs according to the spin-
echo sequence, with TE maintained constant, and T2 was
calculated from the images obtained with 16 diﬀerent TEs
with TR maintained constant. The mean T1 was 375ms,
and the mean T2 was 270ms. The T1 and T2 values in
the report published by Baik et al. (T1Cho = 1513ms, T2Cho
= 269ms) [14] were adopted as the T1 and T2 values for
choline in vivo. The coil sensitivities indicate the signal
intensity of the external reference phantom and the signal
intensity within the imaging area. The signal intensity within
the imaging area was obtained on proton-weighted images
(TE/TR, 15/5000) with a solution phantom introduced into
themeasurementbreastcoilthatwasthesameastheexternal
reference solution.
3.8. Data Processing and Spectral Interpretation at Our
Hospital. The spectroscopic data processing protocol was
saved and linked to the measurement protocol within the
syngo software (Siemens AG Healthcare Sector, Erlangen,
Germany) to ensure that data processing was identical for
each measurement. The spectra were processed by zero-
ﬁlling the 1028 data points to 2048 data points by applying a
Gaussian apodization function of 1.5Hz before fast Fourier
transformation. The scaling factor was 12096. We ﬁtted the
choline peak and water peak with a Gaussian function that
ranged from 3.18 to 3.32ppm for choline and was 4.7ppm
for water. The peak line widths were restricted according to
the following settings; the Cho peaks were recognized as Cho
when the FWHM was less than 10Hz; when the FWHM was
10Hz or more, the peaks no longer ﬁt.
Phase correction was performed manually. The residual
water signal was used for reference (4.7ppm), and the fre-
quency of any resonance detected in the 3.00–3.50ppm spec-
tral region was recorded. Choline peaks at 3.21–3.23ppm
are assigned to phosphocholine (PC) and were evaluated
by using a threshold SNR of 2 [15, 16]. When positive for
choline, water subtraction and baseline correction with a
sixth-order polynomial ﬁt were applied to obtain the ﬂat
baseline of an MR spectrum. The normalized choline signal,
which was calculated automatically, was recorded. When
negative for choline, the numerical value of choline was
recorded as zero.
4. ClinicalSummation:Usefulness for
DifferentialDiagnosis
Thus far, reports on clinical research on proton MR
spectroscopy of the breast have centered on diﬀerentiating
between benign and malignant lesions. However, the possi-
bility of using 1.5T to detect biomarkers of breast cancer has
also been reported in recent years. Below we comment on
thepossibilitiesrelatedtothediagnosticpowerofprotonMR
spectroscopy for breast lesions.
4.1. Diﬀerentiation between Benign and Malignant. The
major papers on the diagnostic performance of proton MR
spectroscopy as a means of diﬀerentiating between benign
and malignant tumors that were published between 1998
and 2009 are listed in Table 1 [5, 15–23]. According to the
data in the nine other papers after excluding our own [23],
sensitivity ranged from 70% to 100%, and speciﬁcity ranged
from 67% to 100%. Sensitivity in the nine articles as a whole
was 88% (165/187), and speciﬁcity was 88% (126/144), and
the diagnostic performance reported was related to lesions of
1cm or greater in size.4 Journal of Oncology
(a)
0
0.1
0.2
0.3
4 3.5 3 2.5
(ppm)
Cho
I: 2.39
P: 3.24
(b)
(c)
100%
20%
(d)
Figure 1: Chemical shift imaging (CSI) of breast cancer. ((a), (b)) Spectroscopy data acquire multitarget volume and multivoxels (a). TR =
1500ms, TE = 270ms, voxel size = 10 × 10 ×15mm3 , the time of acquisition = 7 minutes. The spectrum spans from 2.0 to 4.5ppm (b).
The choline (Cho) peak was detected at 3.24ppm. ((c), (d)) Both spectral map (c) and metabolite map (d) are made by spectroscopy data.
Choline peak is displayed in color map (d). High-signal intensity area (color: red) indicates high-signal intensity from breast cancer.
Table 1: The diagnostic power of proton MR spectroscopy for breast lesions.
Study year No. of malignant
lesions
No. of benign
lesions
Sensitivity (%) Speciﬁcity (%)
No. of
false-positive
ﬁndings
PPV (%)
Roebuck et al. [17] 1998 10 7 70 86 1 88
Kvistad et al. [5] 1999 11 11 82 82 2 82
Cecil et al. [18] 2001 23 15 83 87 2 90
Yeung et al. [19] 2001 24 6 92 83 1 97
Jagannathan et al. [20] 2001 32 14 81 86 2 93
Tes et al. [21] 2003 19 27 89 100 0 100
Huang et al. [15] 2004 18 12 100 67 4 82
Bartella et al. [16] 2006 31 26 100 88 3 91
Sardanelli et al. [22] 2009 19 26 84 88 3 84
Tozaki et al. [23] 2009 91 80 44 85 12 77
Tozaki et al. [23]∗ 2009 34 16 82 69 5 85
∗masses measuring 15mm or more.Journal of Oncology 5
Thespecialcharacteristicofourownstudy[23]isthatwe
performed proton MR spectroscopy before biopsy in order
to exclude any eﬀects of bleeding or inﬂammation after a
biopsy, and Breast Imaging Recording and Data System (BI-
RADS-) MRI [24] category 4 and 5 lesions were the subject
of our study. There were 171 cases, more lesions than in
any of the other studies, but a comparison with the previous
studiesshowedthatsensitivitywasverylow(44%;40/91).We
think the reasons for the low sensitivity were that the target
lesions were small and that nonmass lesions were included.
Actually, when restricted to masses measuring 15mm or
more, sensitivity improved to 82% (28/34).
The ﬁrst study of nonmass lesions by proton MR
spectroscopy was reported by Bartella et al. [25], and the
results were favorable, that is, a sensitivity of 100% and a
speciﬁcity of 85%. By contrast, the results for sensitivity
in our own research [23] were very low, 32% (9/28), and
speciﬁcity was 75% (12/16) (Table 2). One of the reasons
for this is thought to be diﬀerences between the types of
cancersthatwerethesubjectofthestudies.Ductalcarcinoma
in situ (DCIS) accounted for 17% (2/12) of the cancers in
the report by Bartella et al. [25] whereas they accounted for
89% (25/28) of the cancers in our study. The morphologic
patterns of DCIS were variable on MRI and included a
branching-ductal pattern and a scattered clumped pattern
in cases with low tumor density at histology and conﬂuent
clustered rings in those with high tumor density at histology
[23]. The proportion of DCIS might aﬀect the sensitivity
of MR spectroscopy for nonmass lesions. Therefore, the
diagnostic performance for nonmass lesions of proton MR
spectroscopy with the 1.5T MR unit currently being used
does not appear to be satisfactory, and we think it will be
necessary to assess stronger magnetic ﬁelds in the future. It
also appears that in the future, it will be necessary to improve
the coils, optimize the measurement sequence, and increase
the precision of the data postprocessing.
However, false-negative cases have been reported even in
relatively large invasive cancers, and in addition to invasive
ductal carcinoma, they have been reported in medullary
carcinoma [19, 21], mucinous carcinoma [23], and apocrine
carcinoma [23]. The existence of these false-negative cases
corroborates the fact that biopsy must not be avoided on
the basis of negative proton MR spectroscopy ﬁndings alone.
Fibroadenoma [5, 15, 16, 19, 22, 23], tubular adenoma
[17, 18], intraductal papilloma [23], mastopathy (including
benign proliferative disease) [5, 18, 22, 23], inﬂammatory
lesions with atypia [16], and atypical ductal hyperplasia
[16, 22]h a v eb e e nr e p o r t e d .
4.2. Choline Elevation in Breast Parenchyma. The elevated
choline level in breast cancer may be associated with
increased membrane synthesis by replicating cells, however,
benign tissues, such as proliferative ﬁbroadenoma, may also
produce a positive-choline signal [26].
When we measured the proton MR spectroscopy of the
breast parenchyma in 920 cases at our hospital, however,
we observed a choline peak in 12% (113/920), and 32% of
the choline peaks (36/113) were consistent with the choline
that is seen in malignancy (PC; 3.21–3.23ppm) (Figure 2).
The exact reason for this phenomenon is unknown, but
the increase in choline in the breast parenchyma may be
greater than previously thought. This is important in terms
of clinical diagnosis, and caution is required because of the
possibility of intermingling by very weak choline in the
surrounding area, especially when a voxel that is larger than
the lesion is placed.
4.3. Eﬀect of the Contrast Medium. Since breast lesions
are usually detected by MRI after contrast medium has
been injected, we tried performing proton MR spectroscopy
after contrast-enhanced MRI, and the gadolinium contrast
medium appeared to have a very slight eﬀect the MR
spectrumofthelesion.Lenkinskietal.[27]usedona3TMR
unit to conduct a study of the eﬀect of six gadolinium con-
trast media (Magnevist, MultiHance, Omniscan, Optimark,
ProHance, and Dotarem) on MR spectroscopy performed
on phantoms and a rat model of breast cancer. The results
obtained with the phantom showed that the width of the
choline peak broadened with three of the contrast media,
that is, Magnevist, MultiHance, and Dotarem, and the
volume of the peak decreased to an average of about 40%.
The use of negatively-charged chelates may be associated
with the underestimation of the choline level present in the
lesion, and their conclusion was to recommend the use of
neutral chelates for MR spectroscopy of the breast.
We attempted to determine the eﬀect on the choline
spectrum at our hospital by using two diﬀerent contrast
media (negatively-charged chelates and neutral chelates),
Magnevist (gadopentetate dimeglumine, Gd-DTPA) and
Omniscan (gadodiamide, Gd-DTPA-BMA). We used each
of the two contrast media on a diﬀerent day in 30 patients
who had been found to have an enhanced mass, and we
compared the changes in width and height of the choline
peaks.TheWilcoxonsigned-ranktestwasusedtostatistically
analyzethedata.Approvaltoconductthestudywasobtained
from the ethics committee. The results did not show any
statistically signiﬁcant changes in the width or height of the
choline peak due to the contrast media (Figure 3), and no
statistically signiﬁcant diﬀerences in FWHM or T2
∗ during
shimming were observed in the same cases. We think these
ﬁndings suggested that the impact of the contrast medium in
clinical settings in which 1.5T MRI is used is very mild. MR
spectroscopyismorestronglyimpactedbythelocationofthe
tumor (skin and vicinity of the chest wall) and the imaging
conditions, and the impact of the contrast medium appears
to be trivial by comparison.
4.4. Possibilities as a Means of Biomarkers. The potential of
proton MR spectroscopy as a means of biomarkers of breast
cancer has already been investigated in many ex vivo studies.
Lean et al. [28] reported being able to diﬀerentiate Grade I
and II breast cancers from Grade III breast cancers based on
MR spectroscopy ﬁndings in an ex vivo study of ﬁne-needle
aspiration specimens. We have reported similar ﬁndings in
vivo, as described below [29]. In our study, the choline levels
measured by proton MR spectroscopy with a 1.5-T unit6 Journal of Oncology
Table 2: The diagnostic power of proton MR spectroscopy for nonmass lesions.
Study year No. of malignant lesions
No. of
benign
lesions
Sensitivity
(%)
Speciﬁcity
(%) No. of false-positive ﬁndings PPV (%)
Bartella et al.
[25] 2007 12 20 100 85 3 80
invasive ductal carcinoma;
10
ductal carcinoma in situ; 2
ﬁbroadenoma; 1
inﬂammatory lesions with
atypia; 1
atypical ductal hyperplasia; 1
Tozaki et al.
[23]∗ 2009 28 16 32 75 4 69
invasive ductal carcinoma; 2
microinvasion; 1
ductal carcinoma in situ; 25
benign proliferative disease; 4
∗nonmass lesions.
correlated well with the histological prognostic factors, that
is,nucleargrade,estrogenreceptorstatus,andtriple-negative
lesion status. It is hoped that in vivo research on proton MR
spectroscopy to detect biomarkers will contribute to breast
cancer therapy, including drug therapy.
5. ClinicalSummation: Application to
Neoadjuvant Chemotherapy
Theroleofdiagnosticimaginginneoadjuvantchemotherapy
lies in diagnosing the spread of residual tumors after
chemotherapy and in judging the eﬃcacy of the chemother-
apy [2]. There are two very important points in regard to the
diagnosis of the spread of residual lesions after chemother-
apy: “the pattern of tumor spread before chemotherapy” and
“the pattern of tumor shrinkage after chemotherapy, [30]”
and when this information is taken into consideration, it
appears possible to perform breast-conserving surgery safely.
Judging the eﬃcacy of chemotherapy, on the other hand,
means evaluating the chemosensitivity of the tumor in vivo.
Many reports have shown that the variety of information
provided by MRI (tumor diameter, changes in volume, and
changes in blood ﬂow) is more useful than the information
provided by palpation or ultrasonography [31–34]. A great
deal of hope is now being placed in MR spectroscopy and
PET molecular images.
5.1. Prediction of Therapeutic Eﬃcacy. As stated above, since
proton MR spectroscopy has a role in the evaluation of
treatment of breast diseases by providing molecular infor-
m a t i o n ,i ti sr e g a r d e da sa ne ﬀective method for monitoring
the activity of breast cancer and for early prediction of the
eﬃcacy of chemotherapy [35–43]. Accurate assessment of
the response to neoadjuvant chemotherapy is one of the
critical factors for optimizing the chemotherapy regimen
and planning further surgery. The greatest advantages of
early prediction of eﬃcacy are being able to reduce unnec-
essary adverse eﬀects, prevent treatment delays, and avoid
unnecessary administration of expensive drugs that do not
show promise of being eﬀective. We describe several of the
problems below.
5.2. Voxel Size: Variable or Fixed. Since methods that alter
MR spectroscopy voxels according to the size of the tumor
during the course of breast cancer chemotherapy are routine
[36, 40], quantiﬁcation is essential in order to compare
changes in the amount of choline. However, the repro-
ducibility of the quantitative values themselves is a problem,
because when the voxels are altered, shimming accuracy and
the SNR change. We therefore gave priority to obtaining
stabilized voxels that could be compared before and after
treatment and tried a method in which we ﬁx voxel size and
position the voxel at the same site as the lesion.
However, because this is not the standard method,
we ﬁrst investigated its accuracy by making comparisons
with PET/CT in the same patients [39]. The results of the
comparisons of the amount of choline (integral values)
obtained by MR spectroscopy and the standardized uptake
value (SUV) obtained by PET/CT showed that the changes
in the two perfectly paralleled each other [39].
When we ﬁxed the voxel size, there appeared to be
major advantages from a clinical standpoint in terms of
being able to ﬁx the scanning parameters, such as receiver
gain, and easily observe increases in choline within the
unit voxel. On the other hand, one of the disadvantages
of this technique is that tumor metabolism can only be
observed partially in tumors larger than the voxel size. The
other is that the tissue surrounding the tumor is included
in the voxel when the tumor becomes smaller than the
voxel as a result of regression. However, if MR spectroscopy
is used to identify nonresponders early, this disadvantage
is avoidable. Further studies are needed to examine the
advantages and disadvantages of this technique in a larger
number of patients.
5.3. PET/CT versus Proton MR Spectroscopy. There have been
more reports of using PET/CT for early prediction of the
eﬃcacy of chemotherapy for breast cancer than of using
proton MR spectroscopy. The study on the largest number ofJournal of Oncology 7
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Figure 2: Proton MR spectroscopy of the normal breast parenchyma. Coronal 3D contrast-enhanced fat-suppressed MR image (TR/TE,
5.2/2.3)shows nosuspiciousﬁndings(a).Single-voxel spectrumshows acholine (Cho)peakat3.22ppm(b).Water subtractionandbaseline
correction are applied (c). The normalized choline (Cho) signal is 2.03.
cases (n = 64) reported that the evaluations after 2 courses
of therapy were more accurate than the evaluations after
1 course or after 3 courses [44]. We conducted a study to
determine whether proton MR spectroscopy or PET/CT is
more suitable for early prediction of eﬃcacy [41], and we
conducteditaftertwocoursesofchemotherapywhenpredic-
tion of eﬃcacy by PET/CT also was reported to be the most
accurate. The results of the study by the external reference
method with a ﬁxed voxel size (15 × 15 × 15mm) in 16
casesshowedthatprotonMRspectroscopyandPET/CTwere
equivalent [41]. However, whether MR spectroscopy is as
good as PET has not been ﬁrmly established. Further studies
are needed.
5.4. Problems in Early Prediction of Eﬃcacy. Neoadjuvant
chemotherapy usually consists of an anthracycline-based
regimen followed by taxane-based regimens, but because
the early evaluations by MR spectroscopy are no more than
evaluations of the initial anthracycline-based regimen and
are not always consistent with the pathological evaluation
after the completion of chemotherapy, evaluations of eﬃcacy
performed during the initial anthracycline-based regimen
aloneareinadequateforearlypredictionoftheeﬃcacyofthis
method. Although the number of cases has been small, there
have been cases in which the anthracycline-based regimen
was ineﬀective, but the eﬃcacy of subsequent taxane-based
regimens was excellent, and cases in which the opposite was
true. We therefore assessed early prediction of eﬃcacy by
MR spectroscopy in which treatment with an anthracycline-
based regimen alone was performed [43], and the results
indicated that the changes in choline after the second
cycle of chemotherapy as determined by quantitative MR
spectroscopy may be a more sensitive means of predicting
the pathological response than changes in tumor size are.
We think that it is preferable to try making early predictions8 Journal of Oncology
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of the eﬃcacy of neoadjuvant chemotherapy for each of the
individual drugs.
5.5. Appropriate Timing of Early Predictions of Eﬃcacy. Based
on the results described above, proton MR spectroscopy
may not be inferior to PET/CT as a diagnostic method for
early prediction of eﬃcacy in breast cancer. In the next step,
it will be necessary to determine whether it is possible to
predict eﬃcacy by proton MR spectroscopy earlier than after
2c o u r s e s .I nas t u d yo n1 4c a s e s ,M e i s a m ye ta l .[ 36]f o u n d
that the changes in the amount of choline detected at 4T
within the ﬁrst 24 hours after a single course correlated
with clinical eﬃcacy after the completion of chemotherapy.
We showed that the results of an evaluation by proton MR
spectroscopy at 1.5T after one course (several days before
the start of the second course) correlated with pathological
sizeafterthecompletionofchemotherapy[42].However,the
same as in the study by PET/CT [44], it was also possible
to underestimate the eﬃcacy of treatment after one course
more than after two courses. Proton MR spectroscopy is
a technique that is still in the development stage in the
breast disease. In the future, it will be necessary to carefully
evaluate the proper timing of early prediction of the eﬃcacy
of chemotherapy because the underestimated data could be
an obstacle to clinical application.
6. Conclusion
Proton MR spectroscopy in breast diseases provides molec-
ular information that is useful clinically. The very basis of
the spectroscopy method relies on the use of magnets with
higher ﬁeld strength to separate the diagnostic resonances.
With the growing availability of 3T systems, the use of breast
MR spectroscopy for diagnosing lesions and monitoring
response to neoadjuvant chemotherapy will become routine
clinical practice. However, as stated above, there have not
been very many reports on diﬀerential diagnosis between
benign and malignant lesions or on early prediction of the
eﬃcacy of neoadjuvant chemotherapy. The reason is that
many problems must be resolved, including the optimal
measurement sequence for proton MR spectroscopy, diﬀer-
ences between MR units, spectrum interpretation, postpro-
cessing adjustments, and methods of choline quantiﬁcation
(internal reference method or external reference method).
However, if these problems are not resolved, it will be
impossible to ensure the safety and reliability of being able to
use it for cancer treatment (drug therapy). Standardization
of proton MR spectroscopy and multicenter collaborative
research appear to be essential.
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